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Abstract: A series of new (E)-3(5)-[β-(aryl)-ethenyl]-5(3)-phenyl-1H-pyrazoles bearing 
fluorine atoms at different positions of the aryl group have been synthesized starting from 
the corresponding β-diketones. All compounds have been characterized by elemental 
analysis, DSC as well as NMR (1H, 13C, 19F and 15N) spectroscopy in solution and in solid 
state. Three structures have been solved by X-ray diffraction analysis, confirming the 
tautomeric forms detected by solid state NMR. The in vitro study of their inhibitory potency 
and selectivity on the activity of nNOS and eNOS (calcium-calmodulin dependent) as  
well as iNOS (calcium-calmodulin independent) isoenzymes is presented. A qualitative 
OPEN ACCESS
Molecules 2015, 20 15644 
 
 
structure–activity analysis allowed the establishment of a correlation between the presence/ 
absence of different substituents with the inhibition data proving that fluorine groups enhance 
the biological activity. (E)-3(5)-[β-(3-Fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-
pyrazole (13), is the best inhibitor of iNOS, being also more selective towards the other  
two isoforms. 
Keywords: NOS inhibitors; pyrazoles; tautomerism; fluorine derivatives; curcumin; 
crystallography; multinuclear NMR 
 
1. Introduction 
We have been working for the last years on two different topics: (i) nitric oxide synthase (NOS) 
inhibitors [1–3], and (ii) curcumin and curcuminoid pyrazoles [4–7]. This prompted us to study the 
effects of new curcuminoid pyrazoles on the three NOS isoforms and analyze them by structure–activity 
relationships hoping to find potent/isoform specific NOS inhibitors. 
Nitric oxide (NO●) is a free radical that serves as a multifunctional messenger affecting multiple 
aspects of mammalian physiology. Nitric oxide synthase (NOS) catalyzes the formation of NO● from 
the terminal guanidino nitrogen of L-arginine. There are several homologous but separate NOS genes in 
mammals. Endothelial NOS (eNOS) and neuronal NOS (nNOS) enzymes are produced constitutively 
and they are Ca2+-calmodulin dependent [8]. Macrophage NOS is expressed under basal conditions and 
does not depend on calcium for its activity; it is an inducible NOS isoform (iNOS), which is a component 
of the host’s resistance to infection. The use in medicinal chemistry of different inhibitors of the NOS 
isoforms (nNOS, eNOS, iNOS, and mitochondrial NOS or mtNOS [9,10]) is an important goal; several 
families have been explored: guanidines, citrullines, amidines, isothioureas [11,12], imidazoles [13,14], 
benzoxazolinones [15,16] and 1H-indazoles [1,3,17–19]. More recently 4,5-dihydropyrazoles have been 
reported as nNOS/iNOS selective inhibitors [20]. The most relevant contributions to this topic are a 
series of publications that use azines as selective nNOS inhibitors [21–26]. 
The rediscovery of the biological properties of curcumin has led to an impressive number of 
publications [27–39]. Prominent among these compounds are curcuminoid pyrazoles. Besides our  
own contributions [5,6], a large number of papers have been devoted to them due to their interesting 
properties (Figure 1). 
Already in 1991, Flynn et al. prepared pyrazole 1 from curcumin, which is still one of the most 
significant compounds of this family, as well as compound 2, and described their 5-lipooxygenase and 
cyclooxygenase inhibitory properties [40]. Subsequent modification did not improve 1 but other 
pharmacological properties were discovered, including inhibitor of endothelial cell proliferation [41] 
and cytotoxicity [42,43], as well as antioxidant and anti-inflammatory activity [44]. Schubert et al. made 
an important advance in preparing N-substituted pyrazole derivatives such as 3 (aimed at treating 
Alzheimer’s and Parkinson diseases), known as CNB001 [45–47], and 5 (CNB023) [48] and other authors 
prepared 4 that binds to the amyloid β peptide [49]. Compound 6 is an antiplatelet inhibitor [50]. Our 
previous works correspond to compound 1 and to pyrazoles 7–11 (Figure 1) [5,6]. 
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Figure 1. Curcuminoid pyrazoles, from the literature 1–6 and reported in our previous works 
7–11, with the definition of tautomers a (5-styryl) and b (3-styryl). 
In most papers dealing with curcumin, its relationship with iNOS is cited [51–62]. However, there 
are very few papers where curcumin is associated with the nNOS [63,64]. 
This is the first time in which the effects of curcuminoids on the three NOS isoforms have been 
simultaneously examined. Of all the literature pyrazoles related to curcumin [39–49], none report NOS 
assays; only the paper concerning J147, a non-pyrazole neurotrophic drug with iNOS properties, describes 
5 (CNB023), a precursor of J147 [48]. 
In the present publication, we will report the unpublished biological results concerning the pyrazole 
series, 7–11, and the synthesis, structure and biological evaluation of a new series of pyrazoles bearing 
fluorine atoms, 12–16, designed to improve their physicochemical and medicinal properties [65]. 
2. Results and Discussion 
2.1. Synthesis and Characterization by NMR Spectroscopy 
All the compounds discussed in this work were prepared by reaction of hydrazine with the corresponding 
β-diketones [66–68]. With the exception of curcumin, which is commercially available, and was used 
after purification by crystallization from ethanol-water, the β-diketones were obtained as described 
elsewhere, according to the scheme depicted in Figure 2 [4,7]. The synthesis and characterization of 
pyrazoles 1 and 7–11, have been previously described by us [5,6]. Full characterization of pyrazoles  
12–16 is reported in the experimental section. 
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Figure 2. Synthetic scheme used to prepare pyrazoles 12–16, that can exist in two tautomeric 
forms a and b. 
Concerning tautomerism, in the case of 1, both tautomers are identical. In solution, either in DMSO-d6 
or HMPA-d18, pyrazoles 7–10 proved to exist as a mixture of both forms a and b in different ratios: 
7a/7b, 50:50 (HMPA); 8a/8b, 65:35 (HMPA); 9a/9b, 64:36 (DMSO) and 10a/10b, 60:40 (DMSO). For 11, 
a large predominance of 11a (DMSO) and only this form (HMPA) was established [5]. 
The structures of the new pyrazoles 12–16 have been established by 1H, 13C, 15N and 19F-NMR in 
solution and in solid state. All chemical shift and coupling constant data are given in the Supplementary 
files. The assignments of the signals to the different nuclei are based on: (i) homonuclear and heteronuclear 
2D experiments; (ii) the auto-consistency of the coupling constants values; and (iii) the comparison with 
other NH-pyrazoles where tautomerization is blocked [5,69]. From our solution studies in DMSO-d6,  
we conclude that both tautomers coexist: 12a/12b, 67:33; 13a/13b, 60:40; 14a/14b, 54:46; 15a/15b,  
60:40 and 16a/16b, 57:43. In two cases (13 and 16), we have also used HMPA-d18, a solvent with a 
hydrogen-bond basicity larger than that of DMSO-d6, resulting in an 8% population increase of tautomer a 
(see Supplementary Files for 1H-NMR and Table 1 for 19F-NMR data). Using this 8% correction, we have 
prepared a list of a/b proportion for all pyrazoles 7–16 (Table 2). 
As in our previous studies, ratios have been determined by integration of the 1H-NMR signal intensities 
(see Supplementary Files). Moreover, in the present paper tautomers populations have been corroborated 
by integration of the 19F-NMR signal intensities given in Table 1. 
Solid state NMR spectral data indicate the presence of only one form for pyrazoles 12–16, the  
one corresponding to the major tautomer a detected in solution, and also in agreement with the X-ray 
crystallography determination of the structures of 12, 13 and 16 that will be discussed in the next section. 
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Attention should be paid to the upfield effect observed on the 19F-NMR chemical shifts on going from 
solution to solid phase. 
Table 1. 19F-NMR in solution and solid state of pyrazole derivatives (chemical shifts δ in ppm, 
J coupling constants in Hz). 
Compound Solvent (Temp) F2′ F3′ F4′ F5′ 
12 
DMSO-d6  
295 K 
−116.1 (67%) 
−116.8 (33%)    
MAS 300 K −107.7    
13 
DMSO-d6  
295 K 
 
−136.0 (60%) 
3J = 4J = 10.8 
−136.2 (40%) 
3J = 4J = 10.2 
  
DMSO-d6  
360 K 
 −136.0   
HMPA-d18  
295 K 
 
−137.3 (67%) 
−137.6 (33%)   
MAS 300 K  −129.2   
14 
DMSO-d6  
295 K 
−136.4 (54%) 
−137.0 (46%)  
−132.1 (54%)  
−132.8 (46%)  
MAS 300 K −130.7  −126.8  
15 
DMSO-d6  
295 K 
−121.3 (60%) 
−122.1 (40%)   −140.6
MAS 300 K −114.2   −134.8
16 
DMSO-d6  
295 K 
  
−135.4 (57%)  
−136.3 (43%)  
HMPA-d18  
295 K 
  
−136.9 (65%)  
−137.8 (35%)  
CDCl3 295 K   −135.5  
MAS 300 K   −132.6  
Table 2. Proportion of tautomer a (b = 100 − a) for pyrazoles 7 to 16 in DMSO-d6. 
NN
H
R1
R4' 53
R2
R3 '
NN
R1
R4' 35
R2
R3'
H
a bR
2'
R5' R
5'
R2 '
 
Compound 7 8 9 10 11 12 13 14 15 16 
% a 42 [a] 57 [b] 64 60 85 [c] 67 60 54 60 57 
[a] 50% in HMPA-d18; [b] 65% in HMPA-d18; [c] large excess in HMPA-d18. 
We have illustrated the spectra obtained in 19F-NMR, with the example depicted in Figure 3, which 
corresponds to compound (E)-3(5)-[β-(3-fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (13), 
concentration 0.078 M, in the temperature range of 290–360 K. The dynamic NMR experiment has 
permitted us to estimate the barrier separating both tautomers to be 71 kJ·mol−1, by using the Eyring 
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equation: ΔGT‡(kJ·mol−1) = 19.12 × Tc (10.32 + logTc/kc) (kc = Δνmax × π/ 2 ), a valid approach for 
systems in which the populations of the two sites are equal [70] using the following data: Tc = 350 K, 
Δνmax = 79.8, 13a/13b ratio of 60:40 and kc (s−1) = 177. A close value of 69 kJ·mol−1 was found for  
(E)-3(5)-[β-(4-fluoro-3-methoxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (16) when performing a 
similar experiment. 
 
Figure 3. 19F-NMR spectra (left) and 1H-NMR spectra (right) of compound 13 in DMSO-d6 
(11 mg in 0.5 mL) in the temperature range of 290–360 K. 
2.2. Crystal and Molecular Structures 
Suitable single crystals for X-ray diffraction studies were obtained for 12 from ethyl acetate-hexane, 
for 13 from dichloromethane-ethanol-hexane and for 16 from dichloromethane-hexane. In all cases, the 
crystallized molecule corresponds to the a tautomeric form, in agreement with solid NMR data. 
Compounds 12 and 13 are isostructural and crystallize in the monoclinic P21/n space group. For this 
reason, only the former will be described in detail since the results can be extended to the latter. 
Figure 4 shows the labeling of the asymmetric unit of 12 that corresponds to one single molecule. This 
molecule is not completely planar due to the twist of the phenyl ring with respect to the pyrazole moiety, 
the dihedral angle between them is 25.4(2)°. Excluding this phenyl ring, the rest of the atoms slightly 
deviated from the mean molecular plane. This fact suggests an extended electronic delocalization over this 
part of the molecule. 
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Figure 4. ORTEP (Oak Ridge Thermal Ellipsoid Plot) (40% ellipsoid probability) of 12 
showing the labeling of the asymmetric unit. 
Each molecule forms intermolecular hydrogen bonds with the adjacent molecules leading to the 
formation of tetramers as can be shown in Figure 5 and Table 3. Every pyrazole nitrogen atom is 
asymmetrically hydrogen bonded to the phenol group of a different molecule, N1-H1···O1#1 and 
N2···H1A-O1#2 (See footnote [a] in Table 3). The tetramer is closed by the equivalent interactions of 
the latter with the nitrogen atoms on the centrosymmetric molecule to the initial one. The cycle so formed 
consists of N1···O1#1···N2#3-N1#3···O1#2···N2 (#3: 1 − x, 1 − y, 1 − z). Additionally, each molecule 
participates in a second tetrameric unit through its phenol group spreading out the intermolecular 
contacts in a bidimensional way (Figure 5). 
 
Figure 5. View of the packing for 12 showing the tetrameric units. 
Table 3. Hydrogen bonds (Å and °) for compounds 12, 13 and 16. 
Comp D-H···A [a] Symmetry Operations d(D-H) d(H···A) d(D···A) <(DHA)
12 
N1-H1···O1#1  
N2···H1A-O1#2 
#1 –x + 1/2, y + 1/2, −z + 3/2 
#2 x + 1/2, −y + 1/2, z − 1/2 
0.98  
1.01 
1.98  
1.72 
2.899(2)  
2.711(2) 
154.1  
164.3 
13 
N1-H1···O1#1  
N2···H1A-O1#2 
#1 – x + 3/2, y + 1/2, −z + 1/2 
#2 x − 1/2, −y + 3/2, z + 1/2 
1.02  
1.08 
1.86  
1.69 
2.871(3)  
2.736(3) 
171.1  
161.8 
16 N1-H1···N2#1 #1 − x, −y + 2, −z + 1 1.02 1.92 2. 852(2) 150.2 
[a] #1, #2 correspond to symmetry transformations used to generate equivalent atoms. 
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Compound 16 crystallizes in the monoclinic P21/c space group. The asymmetric unit also corresponds 
to one molecule with a labeling scheme analogous to that shown in Figure 4 for compound 12, but 
differently from 12, both substituents on the pyrazole are twisted relative to this ring suggesting that the 
electronic delocalization is not extended (See Supplementary Files). Each molecule interacts with the 
adjacent centrosymmetric one forming dimers linked by symmetric hydrogen bonds between the pyrazole 
nitrogen atoms, N1-H1···N2#1 (Figure 6). No significant additional contacts have been observed. The 
presence of the methoxy group in 16 limits the chances of interactions leading to the formation of only 
isolated dimers instead of the extended network found in compounds 12 and 13. 
 
Figure 6. View of the dimer in 16. 
2.3. NOS Inhibitory Activity 
NOS activity was measured following the conversion of L-3H-arginine to L-3H-citrulline according to 
the Bredt et al. [71] protocol and full details are given in the Experimental Section. The NOS inhibitory 
activities of the whole set of pyrazoles (1, 7–16) are gathered in Table 4. 
In preliminary experiments, we found that compounds 12–16 of the second series were much more 
active against NOS isoforms than the first ones. Therefore, they were assayed at concentrations enough 
to produce NOS inhibition similar to compounds 7–11. As can be seen, 50 μM of 12–16 yields an 
inhibition of NOS isoforms comparable to 1 mM of 1, 7–11. This result means that pyrazoles 12–16 are 
about 20-fold more potent than pyrazoles 1, 7–11. 
A qualitative structure–activity analysis of the data points out that, for the first series, it comes as a 
surprise that while curcumin and the curcuminoids are predominantly iNOS and seldom nNOS inhibitors, 
the curcuminoid pyrazole 1 shows the three activities in comparable amounts being predominantly an 
eNOS inhibitor. A 4-methyl group decreases the potency when there is a 3(5)-methyl group (compare 7 
and 8) but increases it when there is a 3(5)-phenyl group (compare 10 and 11). Concerning potency, the 
best compounds are the derivatives 9 and 7 both showing about 84% inhibition but towards different 
isoforms (nNOS vs. eNOS) followed by 1 (77% towards eNOS). 
For pyrazoles 12–16, all of them 3(5)-phenyl derivatives, it appears that concerning nNOS the best 
compound is 12 but it is equally as potent as an iNOS inhibitor, with the remaining compounds being 
less active. Compound 13 is not only a better iNOS inhibitor, but is also more selective towards the other 
two isoforms than 12. Finally, against eNOS all show similar, but weak, activity. 
When comparing our results with those obtained for two standard NOS inhibitors, 7-nitro-1H-indazole 
and 4,5,6,7-tetrafluoro-1H-indazole [3], but under different conditions (50 μM vs. 1 mM), our curcuminoid 
pyrazoles are more potent and present different selectivities (Table 4). If compound 9 is similar in 
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selectivity (nNOS) to 4,5,6,7-tetrafluoro-1H-indazole, compound 13 is higher in potency (iNOS) to  
7-nitro-1H-indazole, but much more selective. 
Table 4. Percentage of inhibition of nNOS, iNOS and eNOS activities in the presence of the 
tested curcuminoid pyrazoles 1, 7–11 using 1 mM/EtOH and curcuminoid pyrazoles 12–16 
using 50 μM/DMSO, with the most interesting values in bold. Both series compared to control 
(0% inhibition). Experimental data represent the means ± S.E.M. of three independent 
experiments (n = 3) each one performed in triplicate. 
NN
R1
R4'
R2
H3CO
NN
R4'
R3'
R2'
R5'
H H
H
Compounds 1, 7-11 Compounds 12-16  
Compound R 1 R 2 R 4′ nNOS iNOS eNOS Predominant 
1 
 
H OH 51.2 ± 1.2 65.3 ± 2.1 77.4 ± 0.1 eNOS 
7 CH3 H OH 61.7 ± 1.6 45.6 ± 1.8 84.1 ± 0.7 eNOS 
8 CH3 CH3 OH 29.9 ± 0.7 46.4 ± 3.2 19.2 ± 1.8 iNOS 
9 C6H5 H OH 84.9 ± 0.1 63.5 ± 1.9 60.3 ± 1.5 nNOS 
10 C6H5 H OCH3 20.0 ± 0.2 48.0 ± 0.9 23.4 ± 2.9 iNOS 
11 C6H5 CH3 OCH3 19.0 ± 0.6 62.1 ± 1.2 40.6 ± 2.2 iNOS 
Compound R 2′ R 3′ R 4′ R 5′ nNOS iNOS eNOS Predominant 
12 F H OH H 65.9 ± 6.2 65.8 ± 1.2 37.6 ± 1.8 n/iNOS 
13 H F OH H 36.8 ± 1.5 83.7 ± 6.3 37.4 ± 2.3 iNOS 
14 F OH F H 24.1 ± 2.3 33.6 ± 4.7 40.3 ± 1.6 eNOS 
15 F H OH F 38.9 ± 1.4 36.3 ± 1.2 44.2 ± 0.0 eNOS 
16 H OCH3 F H 21.7 ± 0.3 46.0 ± 5.4 39.3 ± 3.5 iNOS 
1H-indazoles [a]         
7-nitro [3] ---- 88.0 84.0 ---- n/iNOS 
4,5,6,7-tetrafluoro [3] ---- 98.7 43.3 67.5 nNOS 
[a] 1 mM. 
In an attempt to go further in the understanding of the effect of the fluorine atom position on the 
inhibitory activity, a statistical analysis of the results was carried out using a Free–Wilson matrix [72–76] 
(see Supplementary Files) differentiating the fluorine atoms according to their position. Considering that 
compounds 1, 7–11 of the first series are 20 times less potent than those of the second series, we have 
divided their percentages of inhibition by 20 and have reported the normalized values together with those 
of the second series of pyrazoles 12–16, in Table 5. 
The hydroxy group at position 3′ significantly lowers the potency towards all isoforms, in the order 
iNOS > nNOS >> eNOS. A fluorine atom at position 5′ also decreases the potency vs. nNOS and iNOS 
but to a lesser degree, and has almost no effect on the eNOS. Fluorine atoms at positions 2′, 3′ and 4′ 
increase the inhibitory activity vs. the three isoforms. The effect is usually larger on the iNOS (66, 84, 46) 
than on the other isoforms, contributing to the selectivity. With respect to the nNOS, the most discriminating 
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groups are, F2′ (largest, 66) and F4′ (lowest, 22), but the position of the fluorine atom seems to have no effect 
(38, 37, 39) on the eNOS. We have graphically represented these conclusions in Figure 7. 
Table 5. NOS values for compounds 1, 7–16 and regression results in percentage units. 
Compound nNOS iNOS eNOS 
1 2.560 3.265 3.870 
7 3.085 2.280 4.205 
8 1.495 2.320 0.960 
9 4.245 3.175 3.015 
10 1.000 2.400 1.170 
11 0.950 3.105 2.030 
12 65.9 65.8 37.6 
13 36.8 83.7 37.4 
14 24.1 33.6 40.3 
15 38.9 36.3 44.2 
16 21.7 46.0 39.3 
F2′ 66 66 38 
F3′ 37 84 37 
F4′ 22 46 39 
F5′ −27 −30 7 
OH-3′ −64 −78 −37 
n 11 11 11 
R2 0.995 0.997 0.994 
 
Figure 7. Circles, increase the activity; rectangles, decrease the activity. The size represents 
the importance of the effect. 
3. Experimental Section 
3.1. General 
All chemicals cited in the synthetic procedures are commercial compounds. Melting points  
were determined by DSC with a SEIKO DSC 220 C connected to a model SSC5200H disk station. 
Thermograms (sample size 0.003–0.005 g) were recorded with a scan rate of 5.0 °C. Column 
chromatography was performed on silicagel (Merck 60, 70–230 mesh) and elemental analyses using a 
Perkin-Elmer 240 apparatus (PerkinElmer, Waltham, MA, USA). 
The nomenclature used in the text and in the experimental is not in accordance with IUPAC rules 
where, for all of the compounds with phenolic hydroxyl groups, the phenol system has the highest 
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priority; however, using IUPAC nomenclature here would be at the expense of comparability and clarity. 
For instance, compound 12 would be (E)-3-fluoro-4-(2-(3-phenyl-1H-pyrazol-5-yl)vinyl)phenol under 
IUPAC rules, rather than (E)-3(5)-[β-(2-fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole. 
Having decided to prioritize comparability over correct nomenclature, we have named all of the compounds 
as pyrazole derivatives (Figure 8). 
 
Figure 8. Atom numbering for NMR assignments.  
3.2. NMR Parameters 
Solution NMR spectra were recorded on a Bruker DRX 400 (9.4 Tesla, 400.13 MHz for 1H, 100.62 MHz 
for 13C, 40.54 MHz for 15N and 376.50 MHz for 19F, (Bruker Española S.A., Madrid, Spain) spectrometer 
with a 5-mm inverse-detection H-X probe equipped with a z-gradient coil (1H, 13C, 15N) and with a QNP 
5 mm probe (19F), at 295 K. Chemical shifts (δ in ppm) are given from internal solvent, DMSO-d6 2.49 
for 1H and 39.5 for 13C, HMPA-d18 2.51 to the upfield multiplet for 1H and 35.8 for 13C. External 
references were used for 15N and 19F, nitromethane and CFCl3, respectively. Coupling constants (J in Hz) 
are accurate to ±0.2 Hz for 1H, ±0.8 Hz for 19F and ±0.6 Hz for 13C. Typical parameters for 1H-NMR 
spectra were spectral width 6500 Hz and pulse width 7.5 μs at an attenuation level of 0 dB. Typical 
parameters for 19F-NMR spectra were spectral width 55 kHz, pulse width 13.75 μs at an attenuation level 
of −6 dB and relaxation delay 1 s. Typical parameters for 13C-NMR spectra were spectral width 21 kHz, 
pulse width 10.6 µs at an attenuation level of −6 dB and relaxation delay 2 s; WALTZ-16 was used for 
broadband proton decoupling; the FIDs were multiplied by an exponential weighting (lb = 2 Hz) before 
Fourier transformation. 2D (1H-13C) gs-HMQC and (1H-13C) gs-HMBC were acquired and processed 
using standard Bruker NMR software and in non-phase-sensitive mode [77]. Gradient selection was 
achieved through a 5% sine truncated shaped pulse gradient of 1 ms. Selected parameters for (1H-13C) 
gs-HMQC and gs-HMBC spectra were spectral width 3500 Hz for 1H and 20.5 kHz for 13C, 1024 × 256 data 
set, number of scans 2 (gs-HMQC) or 4 (gs-HMBC) and relaxation delay 1 s. The FIDs were processed 
using zero filling in the F1 domain and a sine-bell window function in both dimensions was applied 
prior to Fourier transformation. In the gs-HMQC experiments GARP modulation of 13C was used for 
decoupling. Selected parameters for (1H-15N) gs-HMQC spectra were spectral width 6500 Hz for 1H and 
12.5 kHz for 15N, 1024 × 256 data set, number of scans 4, relaxation delay 1 s. The FIDs were processed 
using zero filling in the F1 domain and a sine-bell window function in both dimensions was applied prior 
to Fourier transformation. 
Variable-temperature experiments (DNMR) were recorded with the same spectrometer with a QNP 
5 mm probe and a Bruker BVT 3000 temperature unit was used to control the temperature of the cooling 
gas stream and an exchanger to achieve low temperatures. 
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Solid-state 13C (100.73 MHz) and 15N (40.60 MHz) CPMAS NMR spectra have been obtained on a 
Bruker WB 400 spectrometer (Bruker Española S.A.) at 300 K using a 4 mm DVT probehead. Samples 
were carefully packed in a 4-mm diameter cylindrical zirconia rotor (Bruker Española S.A.) with Kel-F 
end-caps. Operating conditions involved 3.2 μs 90° 1H pulses and decoupling field strength of 86.2 kHz 
by TPPM sequence. 13C spectra were originally referenced to a glycine sample and then the chemical 
shifts were recalculated to the Me4Si (for the carbonyl atom (glycine) δ = 176.1 ppm) and 15N spectra to 
15NH4Cl and then converted to nitromethane scale using the relationship: δ 15N (nitromethane) = δ 15N 
(ammonium chloride) − 338.1 ppm. Typical acquisition parameters for 13C-CPMAS were: spectral width, 
40 kHz; recycle delay, 30–100 s; acquisition time, 30 ms; contact time, 5 ms; and spin rate, 12 kHz. In 
order to distinguish protonated and unprotonated carbon atoms, the NQS (Non-Quaternary Suppression) 
experiment by conventional cross-polarization was recorded; before the acquisition the decoupler is 
switched off for a very short time of 25 μs [78–80]. For 15N, CPMAS were: spectral width, 40 kHz; 
recycle delay, 30–100 s; acquisition time, 35 ms; contact time, 6 ms; and spin rate, 6 kHz. 
Solid-state 19F (376.94 MHz) NMR spectra have been obtained on a Bruker WB 400 spectrometer 
(Bruker Española S.A.) using a MAS DVT BL2.5 X/F/H double resonance probehead. Samples were 
carefully packed in 2.5 mm diameter cylindrical zirconia rotors with Kel-F end-caps. Samples were spun 
at the magic angle at rates of 25 kHz and the experiments were carried out at ambient probe temperature. 
The typical acquisition parameters 19F{1H} MAS were: spectral width, 75 kHz; recycle delay, 10 s; 
pulse width, 2.5 μs and proton decoupling field strength of 100 kHz by SPINAL-64 sequence; recycle 
delay, 10 s; acquisition time, 25 ms; 128 scans; and spin rate, 25 kHz. 
The 19F spectra were referenced to ammonium trifluoroacetate sample and then the chemical shifts 
were recalculated to the CFCl3 (δCF3CO2−NH4+ = −72.0 ppm). 
3.3. General Procedure for the Preparation of Pyrazole Derivatives (12–16) 
Compounds 12–16 were prepared by reacting the corresponding β-diketones [4,7] (1 mmol) with 
hydrazine hydrate 98% (1.5 mmol) in acetic acid (5 mL). After heating at reflux for 2 h the reaction 
mixture was poured into water. The precipitate was filtered off, washed with water and dried. The solid 
was purified by column chromatography using ethyl acetate/hexane as eluent or by crystallization. 
(E)-3(5)-[β-(2-Fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (12). Compound 12 was 
prepared from (E)-5-(2-fluoro-4-hydroxyphenyl)-1-phenylpent-4-ene-1,3-dione. The compound was 
purified by column chromatography using ethyl acetate/hexane as eluent (7:3). Yellow crystals were obtained 
after recrystallization from EtOH/H2O. Yield: (290 mg, 82%); mp: 217.3 °C; 1H-NMR: (400.13 MHz, 
DMSO-d6) δ = 6.60 (3JF = 12.8, 4JH5′ = 2.4, H3′), 6.65 (3JH6′ = 8.5, 4JH3′ = 2.4, H5′), 6.91 (H4), 6.99  
(3JH7 = 16.9, H6), 7.17 (3JH6 = 16.9, H7), 7.30 (Hp), 7.41 (Hm), 7.53 (m, H6′), 7.80 (Ho), 10.12 (OH), 
13.06 (67%, NH), 13.23 (33%, NH); 13C-NMR: (100.62 MHz, DMSO-d6) δ = 99.3 (33% C4), 100.0 
(67% C4), 102.8 (2JF = 24.3, C3′), 112.3 (C5′), 114.9 (C6), 122.0 (C7), 122.1 (C1′), 125.1 (Co), 127.4 (Cp), 
128.2 (C6′), 128.7 (Cm), 133.6 (Ci), 142.3 (67% C5), 142.9 (33% C5), 150.9 (67%, C3), 151.0 (33%, C3), 
158.7 (C4′), 160.5 (1JF = 247.3, C2′); 19F-NMR: (376.50 MHz, DMSO-d6) δ = −116.1 (67%), −116.8 
(33%); 13C-NMR: (100.73 MHz, CPMAS) δ = 96.9 (C4), 108.0 (C3′), 113.6 (C5′), 117.9 (C6, C1′), 122.0 
(C7), 124.3 (Co), 126.5 (Cm, Cp), 128.5 (C6′), 130.2 (Ci), 144.0 (C5), 152.2 (C3), 156.2 (C4′), 161.4/158.8 
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(C2′); 15N-NMR: (40.60 MHz, CPMAS) δ = −111.9 (N2), −177.2 (N1); 19F-NMR: (376.94 MHz, MAS)  
δ = −107.7. Anal. calcd. for C17H13FN2O: C 72.85, H 4.67, N 9.99. Found: C 72.31, H 4.58, N 9.96. 
(E)-3(5)-[β-(3-Fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (13). Compound 13 was 
prepared from (E)-5-(3-fluoro-4-hydroxyphenyl)-1-phenylpent-4-ene-1,3-dione.The compound was 
obtained as yellow crystals after recrystallization from EtOH/CH2Cl2/hexane. Yield: (500 mg, 51%); 
mp: 231.3 °C; 1H-NMR: (400.13 MHz, DMSO-d6) δ = 6.85 (60%, H4), 6.90–7.24 (40% H4, H6, H7, H5′, 
H6′), 7.24–7.51 (H2′, Hm, Hp), 7.76 (40%, Ho), 7.80 (60%, Ho), 10.03 (40%, OH), 10.12 (60%, OH), 
13.05 (60%, NH), 13.25 (40%, NH); 13C-NMR: (100.62 MHz, DMSO-d6) δ = 99.3 (40%, C4), 100.0 
(60%, C4), 113.4 (2JF = 18.6, C2′), 114.0 (60%, C6), 117.9 (60%, C5′), 119.7 (40%, C6 and 40%, C5′), 
123.1 (40%, C6′), 123.4 (60%, C6′), 125.1 (Co), 127.4 (60%, Cp), 128.1 (60%, C7), 128.5 (40%, C7 and 
40%, Cp), 128.6 (60%, Cm), 128.8 (40%, Cm), 129.0 (60%, C1′ and 40%, Ci), 129.3 (40%, C1′), 133.6 
(60%, Ci), 142.2 (60%, C5), 142.8 (40%, C5), 144.5 (2JF = 12.7, 40%, C4′), 145.0 (2JF = 12.3, 60%, C4′), 
150.9 (60%, C3), 151.1 (40%, C3), 151.2 (1JF = 240.8, C3′). 15N-NMR: (40.54 MHz, DMSO-d6) δ = −179.7 
(40%, N1), −177.3 (60%, N1). 19F-NMR: (376 MHz, DMSO-d6) δ = −136.0 (3JH2′ = 4JH5′ = 10.8, 60%, 
F3), −136.2 (3JH2′ = 4JH5′ = 10.2, 40%, F3); 13C-NMR: (100.73 MHz, CPMAS) δ = 97.9 (C4), 109.1 (C2′), 
114.7 (C5′), 122.9 (C6′), 125.6 (C6), 126.3 (Co), 128.1 (Cm, Cp), 130.4 (C7), 131.6 (C1′), 132.3 (Ci), 143.1 
(C5), 144.9 (C4′), 151.8 (C3), 156.9/154.6 (C3′); 15N-NMR: (40.60 MHz, CPMAS) δ = −120.0 (N2), 
−168.5 (N1); 19F-NMR: (376.94 MHz, MAS ) δ = −129.2; Anal. calcd. for C17H13FN2O: C 72.85, H 
4.67, N 9.99. Found: C 72.54, H 4.70, N 9.89. 
(E)-3(5)-[β-(2,4-Difluoro-3-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (14). Compound 14 was 
prepared from (E)-5-(2,4-difluoro-3-hydroxyphenyl)-1-phenylpent-4-ene-1,3-dione. The compound 
was purified by column chromatography using ethyl acetate/hexane as eluent (7:3) to give a pale yellow 
solid. Yield: (319 mg, 59%); mp: 195.9 °C; 1H-NMR: (400.13 MHz, DMSO-d6) δ = 6.98–7.23 (H4,  
H6, H7, H5′, H6′), 7.30 (Hp), 7.42 (Hm), 7.80 (Ho), 10.30 (OH), 13.17 (54%, NH), 13.33 (46%, NH);  
13C-NMR: (100.62 MHz, DMSO-d6) δ = 99.9 (46%, C4), 100.7 (54%, C4), 111.9 (2JF = 18.6, C5′), 115.9 
(3JF = 8.2, 3JF = 3.6, C6′), 117.8 (C6), 120.7 (46%, C1′), 121.3 (54%, C1′), 123.6 (C7) 125.1 (Co), 127.6 
(Cp), 128.8 (Cm), 133.5 (Ci), 134.0 (2JF = 2JF = 16.1, C3′), 141.8 (54%, C5), 143.0 (46%, C5), 150.2  
(1JF = 245.6, 3JF = 5.8, C2′), 151.0 (54%, C3), 151.7 (1JF = 240.6, C4′), 153.3 (46%, C3); 15N-NMR:  
(40.54 MHz, DMSO-d6) δ = −178.3 ( 54%, N1); 19F-NMR: (376.50 MHz, DMSO-d6) δ = −137.0 (46%, 
F2), −136.4 (54%, F2), −132.8 (46%, F4), −132.1 (54%, F4); 13C-NMR: (100.73 MHz, CPMAS) δ = 97.1 
(C4), 111.2 (C5′), 119.4 (C6′), 121.7 (C6, C1′), 123.6 (C7), 126.8 (Ci, Co), 129.0 (Cp), 132.3 (Cm), 135.5 
(C3′), 142.5 (C5), 150.1 (C2′), 153.1 (C4′), 153.7 (C3); 15N-NMR: (40.60 MHz, CPMAS) δ = −191.7 (N1), 
−93.9 (N2); 19F-NMR: (376.94 MHz, MAS) δ = −130.7 (F2), −126.8 (F4). Anal. calcd. for C17H12F2N2O: 
C 68.45, H 4.05, N 9.39. Found: C 68.57, H 4.09, N 9.22. 
(E)-3(5)-[β-(2,5-Difluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (15). Compound 15 was 
prepared from (E)-5-(2,5-difluoro-4-hydroxyphenyl)-1-phenylpent-4-ene-1,3-dione. The compound 
was purified by column chromatography using ethyl acetate/hexane as eluent (5:5) to give a pale yellow 
solid. Yield: (319 mg, 59%); mp: 232.6 °C; 1H-NMR: (400.13 MHz, DMSO-d6) δ = 6.78 (4JF5 = 7.4, 
3JF2 = 11.6, H3′), 6.91(60% H4), 6.99 (40% H4), 7.06 (3JH7 = 16.6, H6), 7.15 (3JH6 = 16.6, H7), 7.31 (Hp), 
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7.42 (Hm), 7.58 (H6′), 7.80 (Ho), 10.60 (OH), 13.12 (60%, NH), 13.28 (40%, NH); 13C-NMR: (100.62 MHz, 
DMSO-d6) δ = 99.6 (40%, C4), 100.6 (60%, C4), 105.0 (2JF2 = 26.6, C3′), 113.4 (2JF5 = 21.1, 3JF2 = 5.4, 
C6′), 114.9 (60%, C1′), 115.3 (40%, C1′), 116.2 (60%, C6), 120.1 (40% C6), 120.8 (60% C7), 122.0 (40% 
C7), 125.1 (Co), 127.5 (60%, Cp), 128.3 (40%, Cp), 128.7 (Cm), 133.5 (Ci), 142.0 (60%, C5), 143.0 
(40%, C5), 145.7 (C4′), 148.1 (1JF = 236.9, C5′), 151.0 (C3), 155.7 (1JF = 244.6, C2′); 15N-NMR: (40.54 MHz, 
DMSO-d6) δ = −178.6 ( 60%, N1); 19F-NMR: (376.50 MHz, DMSO-d6) δ = −140.6 (F5), −122.1(40% 
F2), −121.3 (60%, F2); 13C-NMR: (100.73 MHz, CPMAS) δ = 98.4 (C4), 109.8 (C3′), 110.6 (C6′), 116.8 
(C6), 119.8 (C1′), 124.9/123.7 (C7), 128.1 (Co), 128.9 (Cm), 129.3 (Ci), 130.9 (Cp), 143.9 (C5), 148.0 
(C4′), 148.9 (C3), 153.5/150.9 (C5′), 157.5/154.8 (C2′); 15N-NMR: (40.60 MHz, CPMAS) δ = −141.1 (N2), 
−152.2 (N1); 19F-NMR: (376.94 MHz, MAS) δ = −134.8 (F5), −114.2 (F2). Anal. calcd. for C17H12F2N2O: 
C 68.45, H 4.05, N 9.39. Found: C 68.14, H 4.16, N 9.20. 
(E)-3(5)-[β-(4-Fluoro-3-methoxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (16). Compound 16 was 
prepared from (E)-5-(4-fluoro-3-methoxyphenyl)-1-phenylpent-4-ene-1,3-dione. The compound was 
obtained as yellow crystals after recrystallization from CH2Cl2/hexane. Yield: (499 mg, 55%); mp: 150.3 °C; 
1H-NMR: (400.13 MHz, DMSO-d6) δ = 3.90 (OCH3), 6.90 (57%, H4), ~7.0 (43%, H4), 7.06–7.26 (H6, 
H7, H5′, H6′) 7.20–7.50 (H2′, Hm, Hp), 7.77 (43%, Ho), 7.80 (57%, Ho), 13.10 (57%, NH), 13.29 (43%, 
NH); 13C-NMR: (100.62 MHz, DMSO-d6) δ = 56.0 (OCH3), 99.4 (43%, C4), 100.3 (57%, C4), 110.9 (C2′), 
115.9 ( 2JF ≈ 18, 57% C5′, 57% C6), 116.0 ( 2JF ≈ 23, 43%, C5′), 119.4 (57% C6′, 43% C6), 121.5 (43%, 
C6′), 125.1 (Co), 127.4 (57%, Cp), 128.1 (43%, Cp), 128.3 (43%, C7), 128.7 (57% Cm), 128.9 (57%, 
C7), 129.0 (C1′, 43% Cm), 133.5 (57%, Ci), 134.1 (43%, Ci), 142.0 (57%, C5), 142.9 (43%, C5), 147.4 
(2JF = 10.9, C3′), 150.9 (C3), 151.1 (1JF ≈ 246.1, 43%, C4′), 151.3 (1JF ≈ 249.5, 57%, C4′); 15N-NMR:  
(40.54 MHz, DMSO-d6) δ = −179.2 (43%, N1), −177.6 (57%, N1); 19F-NMR: (376.50 MHz, DMSO-d6) 
δ = −136.3 (43%), −135.4 (57%); 13C-NMR: (100.76 MHz, CPMAS) δ = 56.7 (OCH3), 102.7 (C4), 113.8 
(C2′), 114.2 (C5′), 115.0 (C6), 118.4 (C6′), 124.3/127.2 (Co), 128.3 (Cm, Cp), 130.5 (C7), 133.6 (C1′, Ci), 
142.1 (C5), 148.2 (C3′), 152.1 (C3, C4′); 15N-NMR: (40.60 MHz, CPMAS) δ = −181.1(N1), −94.7 (N2); 
19F-NMR: (376.94 MHz, MAS) δ = −132.6; Anal. calcd. for C18H15FN2O: C 73.45, H 5.14, N 9.52. 
Found: C 73.13, H 5.13, N 9.60. 
3.4. In Vitro nNOS, iNOS and eNOS Activities Determination 
L-Arginine, L-citrulline, N-(2-hydroxymethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES),  
D-L-dithiothreitol (DTT), leupeptin, aprotinin, pepstatin, phenylmethyl-sulfonyl fluoride (PMSF), 
hypoxantine-9-β-D-ribofuranosid (inosine), ethylene glycol-bis-(2-aminoethylether)-N,N,N′,N′-tetraacetic 
acid (EGTA), bovine serum albumin (BSA), Dowex-50W (50 X 8–200), FAD, NADPH and 5,6,7,8-
tetrahydro-L-biopterin dihydrochloride (H4-biopterin) were obtained from Sigma-Aldrich Química 
(Madrid, Spain). L-[3H]-arginine monohydrochloride (45–70 Ci/mmol, 1 mCi/mL) was obtained from 
Perkin Elmer Life Sciences (PerkinElmer). Tris(hydroxymethyl)aminomethane (Tris-HCl) and calcium 
chloride were obtained from Merck (Darmstadt, Germany). Calmodulin from bovine brain was obtained 
from Alexis Biochemicals (Enzo Life Sciences, Grupo Taper, Seville, Spain), recombinant iNOS (specific 
activity of 3.9 μmol/min/mg protein) and eNOS (Cayman Chemical, specific activity 3 μmol/min/mg 
protein) were obtained from Cayman Chemical (Vitro S.A, Madrid, Spain). 
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For nNOS activity determination, C57BL/6 mice (3-months old, 25–30 g) (The Jackson Laboratory, 
Bar Harbor, Maine, ME, USA) were housed in the animal facility of the University of Granada under 
specific pathogen-free conditions, and in a controlled 12 h light/dark cycle at 22 ± 2 °C. Mice had unlimited 
access to water and rodent chow until the day of the experiment. All experiments were performed 
according to the Spanish Government Guide and the European Community Guide for animal care. The 
experimental paradigm was published elsewhere [81]. Briefly, mice were killed by cervical dislocation 
and brain was quickly collected, washed, and homogenized in an ice-cold buffer (51 mM Tris, 1 mM DTT, 
10 μg/mL leupeptin, 10 μg/mL pepstatin, 10 μg/mL aprotinin, 1 mM PMSF, pH 7.6). The crude homogenate 
was centrifuged twice at 1000 g at 4 °C, and sonicated (10 s × 6). Aliquots of the supernatant were either 
stored at −80 °C for total protein quantification [82] or immediately used for nNOS activity measurement. 
For iNOS and eNOS activity determination, recombinant enzymes were used. 
The rationale for the use of different sources of pure NOS isoforms comes from their relative abundance 
in normal tissue. Neuronal NOS (nNOS) is abundant in the brain, and it is a suitable source to obtain a pure, 
endogenous form, allowing the study of its kinetic properties [83]. However, iNOS is not constitutively 
expressed in normal tissue (or it is expressed at very low level), and it is only present in high amounts 
during inflammation; therefore, it is much more convenient to obtain it from a commercial source.  
In the case of eNOS, it is also expressed at low levels in vascular areas and, although it may be induced 
during inflammation, this seems to only occur in neutrophils. Thus, endogenous source of eNOS is also 
not appropriate for in vitro assays. 
NOS activity was measured following the conversion of L-3H-arginine to L-3H-citrulline according to 
the Bredt et al. protocol [71]. Enzyme activity was referred as pmol L-3H-citrulline/min/mg protein. The 
final incubation volume was 100 μL and consisted of 10 μL of an aliquot of homogenized brain (for 
nNOS measurement) or recombinant enzyme (for iNOS or eNOS measurement) added to a buffer with 
a final concentration of 25 mM Tris-HCl, 0.5 mM DTT, 30 μM H4-biopterin, 10 μM FAD, 0.5 mM 
inosine, 1 mg/mL BSA, 0.5 mM CaCl2 (or 1 mM for iNOS measurement), 10 μM L-arginine, and 50 nM 
L-[3H]-arginine, 10 μg/mL calmodulin (only for constitutive isoforms), at pH 7.6. Final volume also 
include 10 μL of each pyrazole compound dissolved in EtOH or DMSO to give a final concentration  
of 1 mM or 50 μM, respectively. The activity of the different NOS isoforms was also assayed in the 
presence of each vehicle (EtOH or DMSO) to discard any non-specific effect of the compounds. Neither 
EtOH nor DMSO had significant effects of the NOS activity measured. The reaction was started by the 
addition of 10 μL of NADPH (0.75 mM final) and continued for 30 min at 37 °C. Control incubations 
were performed by the omission of NADPH. The reaction was stopped adding 400 μL of cold 0.1 M 
HEPES, 0.1 M EGTA, and 0.175 mg/mL L-citrulline, pH 5.5. The reaction mixture was decanted onto 
a 2 mL column packet with Dowex-50W ion-exchange resin (Na+ form) and eluted with 1.2 mL of water. 
L-3H-citrulline was quantified by liquid scintillation counting in a Beckman LS-6000 system (Beckman 
Coulter, Fullerton, CA, USA). The retention of L-[3H]-arginine in this process was greater than 98%. 
Specific enzyme activity was determined by subtracting the control value. Statistical analysis: Data are 
expressed as the mean ± SEM. Statistical analysis was performed by Student’s t-test. A p < 0.05 was 
considered statistically significant. 
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3.5. Single-Crystal X-ray Analysis 
Data collection for 13 and 16 was carried out at room temperature on a Bruker Smart CCD diffractometer 
and on a Xcalibur, Atlas CCD diffractometer for 12, using in all cases graphite-monochromated Mo-Kα 
radiation (λ = 0.71073 Å) operating at 50 kV and 40 mA for 12, at 50 kV and 30 mA for 13 and 16. The 
exposure times were 3.37 s for 12 and 20 s for 13 and 16 in omega. 
A summary of the fundamental crystal and refinement data is given in Table 6. The structures were 
solved by direct methods and refined by full-matrix least-squares procedures on F2 (SHELXL-97) [84]. 
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were included in their 
calculated positions and refined riding on the respective carbon atoms. 
Table 6. Crystal data and Refinement Data for 12, 13 and 16. 
Crystal Data 12 13 16 
CCDC 1040404 1040405 1040406 
Empirical formula C17H13FN2O C17H13FN2O C18H15FN2O 
Formula wt 280.29 280.29 294.32 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group P21/n P21/n P21/c 
a/Å 12.5535(10) 12.3701(12) 16.245(5) 
b/Å 7.4573(4) 7.4538(7) 12.187(4) 
c/Å 15.0727(11) 15.2521(15) 7.559(2) 
a α/° 90 90 90 
b β/° 106.759(8) 105.101(2) 94.205(6) 
γ/° 90 90 90 
V/Å3 1351.1(2) 1357.7(2)  3280.0(3)  
Z 4 4 4 
Dc/g/cm3 1.378 1.371 1.310 
μ(Mo-Ka)/mm−1 0.097 0.096 0.091 
F(000) 584 584 616 
θ range/° 3.39 to 25.01 1.90 to 27.00 1.26 to 27.00 
Index ranges −14,−8,−14 to 14, 8, 17 −15,−9,−19 to 15, 8, 17 −20,−15,−9 to 20, 15, 5 
Reflections collected 5657 10842 13044 
Unique reflections 2370 2972 3259 
[Rint] [0.0278] [0.0564] [0.0593] 
Completeness to θ 99.7% 99.7% 99.9% 
Data/restraints/params 2370/0/190 2972/0/192 3259/0/199 
Goodness-of-fit on F2 0.997 0.997 0.995 
R1 0.0437 0.0507 0.0379 
(reflns obsd) [I > 2 s(I)] [a] (1664) (1415) (1548) 
wR2 (all data) [b] 0.1218 0.1631 0.0867 
[a] R1 = Σ||Fo| − |Fc||/Σ|Fo|; [b] wR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}. 
CCDC 1040404, 1040405 and 1040406 contain the supplementary crystallographic data for this 
paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html 
(or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: 
deposit@ccdc.cam.ac.uk). 
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4. Conclusions 
We have evaluated and compared the potency and selectivity of two series of curcuminoid pyrazoles, 
compounds 7–11 without fluorine and compounds 12–16 containing fluorine, as inhibitors of the different 
nitric oxide synthase (NOS) isoforms, and found that as a whole they are mostly iNOS inhibitors, contrary 
to the one derived from curcumin, pyrazole 1, which is predominantly eNOS. One of the most interesting 
compounds is (E)-3(5)-[β-(3-fluoro-4-hydroxyphenyl)-ethenyl]-5(3)-phenyl-1H-pyrazole (13), as it is 
not only the best inhibitor of iNOS, but also more selective towards the other two isoforms. 
Tautomerism studies on both series have been achieved by means of multinuclear NMR (DMSO and 
HMPA) to establish the predominant tautomer, 5-styryl a or 3-styryl b, in each case. The effect of the 
4-methyl group in the pyrazole ring, which increases the average potency in the 3(5)-methyl series and 
decreases it in the 3(5)-phenyl series, seems related to the fact that, in the first case, there is a change of 
tautomerism (7b vs. 8a), while in the second one, both tautomers are the same (10a and 11a). The most 
potent eNOS inhibitor, 7, has the lowest percentage of a tautomer. 
The analysis of substituent effects on the percentages of NOS inhibition demonstrates the importance 
of the introduction of fluorine atoms and opens a new avenue to search for new active substances. 
Supplementary Files 
Tables containing the complete 1H, 13C, 15N and 19F-NMR set of data (chemical shifts and coupling 
constants) in solution and in solid state. The ORTEP plots (40% ellipsoid probability) of 13 and 16 
showing the labeling of their asymmetric units. Figures corresponding to the in vitro nNOS, iNOS and 
eNOS activities determination. The Free–Wilson matrix used to obtain the statistical results of Table 5, 
can be accessed at: http://www.mdpi.com/1420-3049/20/09/15643/s1. 
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